Risk Factors Identified for Transfusion-Related Acute Lung Injury in Critically Ill Patients

By Will Boggs, MDTransfusion factors and patient characteristics contribute to the risk of acute lung injury (ALI) following blood transfusions in critically ill patients, according to a report in the November 1st issue of the American Journal of Respiratory and Critical Care Medicine. "Critically ill patients, their families, and physicians need to be aware that […]

Expert Viewpoint: William J. Gradishar, MD

Professor, Division of Hematology and Medical OncologyNorthwestern UniversityThe Feinberg School of MedicineChicago, IL William J. Gradishar, MD, is Professor of Medicine in the Division of Hematology and Medical Oncology at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. […]

Risks of Transfusion

Bruce D. Spiess, MD, FAHAIntroductionBlood transfusion has evolved into a mainstay medical therapy. It has never undergone efficacy and safety testing the way in which a drug would be tested for approval by the US Food and Drug Administration.[1,2] Today, some 107 years after Karl Landsteiner discovered the ABO histocompatibility antigens, we are still learning […]

Characteristics of Patients Prescribed Angiotensin-Converting Enzyme Inhibitors

Characteristics of Patients Prescribed Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, or the Combination at an Urban Medical CenterGhania Masri, MD; Kristi Bledsoe, PharmD; Carlos Palacio, MD Abstract Background: The realization that angiotensin-converting enzyme (ACE) inhibitors do not provide complete blockade of angiotensin II synthesis has resulted in an increased use of combinations of ACE inhibitors […]

FDA Safety Changes: Pexeva, Vfend, Suprane

News Author: Yael WaknineCME Author: Yael Waknine The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise of the risk for serotonin syndrome in patients receiving concomitant treatment with paroxetine mesylate and triptans, drug interactions between voriconazole and efavirenz requiring dose adjustments for both drugs when used concomitantly, and the risk […]